| 查看: 1057 | 回复: 1 | |||
| 当前主题已经存档。 | |||
huajieyu464木虫 (正式写手)
|
[交流]
新的治疗膝关节炎药物
|
||
|
Naproxcinod (formely HCT 3012) Inflammation in osteoarthritis - phase 3 Naproxcinod is NicOx’ lead product, in phase 3 clinical development for the treatment of the signs and symptoms of osteoarthritis. It is a unique nitric oxide-donating anti-inflammatory and the first of the CINOD class (COX-Inhibiting Nitric Oxide Donators). NicOx aims to develop naproxcinod as a powerful anti-inflammatory agent with no detrimental effects on blood pressure and good gastrointestinal tolerability and safety. Top-line results from the first phase 3 study were successful. This represents an important step towards NicOx’ goal of making naproxcinod the drug-of-choice for osteoarthritis patients. |
回复此楼» 猜你喜欢
三年实验室工作经历，一志愿华中农业大学微生物，总分288求调剂
已经有2人回复
-
膳食补充剂合规性交流
已经有0人回复
-
药物学论文润色/翻译怎么收费?
已经有84人回复
-
一志愿浙大药学求调剂
已经有1人回复
-
070700求调剂
已经有1人回复
-
高温高压反应求助
已经有4人回复
-
求调剂总分327
已经有0人回复
-
药学B区求调剂
已经有0人回复
-
重庆医科大学-人工智能医学学院
已经有0人回复
-
重庆医科大学-人工智能医学学院
已经有0人回复
